GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
| Mar2021 | ₹-442 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | Negative | |
| Mar2021 | ₹-442 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹62,362.0 Cr | 1.1% | 1.7% | 26.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,989.0 Cr | 1.7% | 6.4% | 12.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,471.0 Cr | 3% | 2.8% | 0.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,290.0 Cr | 2.3% | 9.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹117,820.0 Cr | 0.3% | 6.1% | -3.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,730.0 Cr | -0.1% | 8.9% | 1.9% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.1% |
1.7% |
26.8% |
| SENSEX | 0.9% |
4.2% |
-6% |
You may also like the below Video Courses